Price T Rowe Associates Inc Alvotech Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Alvotech stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,389,911 shares of ALVO stock, worth $11.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,389,911
Previous 1,401,421
0.82%
Holding current value
$11.1 Million
Previous $13.6 Million
6.46%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALVO
# of Institutions
51Shares Held
16.4MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA4.23MShares$33.7 Million0.0% of portfolio
-
Bracebridge Capital, LLC2.71MShares$21.5 Million14.1% of portfolio
-
Howard Marks Oaktree Capital Management LP | Los Angeles, Ca1.56MShares$12.4 Million0.39% of portfolio
-
Littlejohn & CO LLC1.32MShares$10.5 Million11.48% of portfolio
-
Heights Capital Management, Inc San Francisco, CA1.09MShares$8.68 Million2.65% of portfolio
About Alvotech
- Ticker ALVO
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 248,650,000
- Market Cap $1.98B
- Description
- Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...